Stocks & Investing
Stocks and Investing
Stocks and Investing
Mon, July 17, 2023
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
Andrew Fein Reiterated (ABOS) at Strong Buy and Held Target at $15 on, Jul 17th, 2023
Andrew Fein of HC Wainwright & Co., Reiterated "Acumen Pharmaceuticals, Inc." (ABOS) at Strong Buy and Held Target at $15 on, Jul 17th, 2023.
Andrew has made no other calls on ABOS in the last 4 months.
There is 1 other peer that has a rating on ABOS. Out of the 1 peers that are also analyzing ABOS, 0 agree with Andrew's Rating of Hold.
This is the rating of the analyst that currently disagrees with Andrew
- Judah Frommer of "Credit Suisse" Maintained at Buy with Decreased Target to $13 on, Tuesday, March 28th, 2023
